Egetis Therapeutics (P0F) Stock Overview
A pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
P0F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Egetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.55 |
| 52 Week High | SEK 0.59 |
| 52 Week Low | SEK 0.25 |
| Beta | 0.78 |
| 1 Month Change | 17.52% |
| 3 Month Change | 27.31% |
| 1 Year Change | 77.42% |
| 3 Year Change | -14.06% |
| 5 Year Change | -4.51% |
| Change since IPO | -63.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| P0F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.2% | -1.0% | 2.5% |
| 1Y | 77.4% | 2.4% | 8.8% |
Return vs Industry: P0F exceeded the German Biotechs industry which returned 2.3% over the past year.
Return vs Market: P0F exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| P0F volatility | |
|---|---|
| P0F Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: P0F's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: P0F's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 42 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company’s products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| P0F fundamental statistics | |
|---|---|
| Market cap | €214.38m |
| Earnings (TTM) | -€31.71m |
| Revenue (TTM) | €5.78m |
Is P0F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P0F income statement (TTM) | |
|---|---|
| Revenue | SEK 62.40m |
| Cost of Revenue | SEK 50.00m |
| Gross Profit | SEK 12.40m |
| Other Expenses | SEK 354.90m |
| Earnings | -SEK 342.50m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 29, 2026
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 19.87% |
| Net Profit Margin | -548.88% |
| Debt/Equity Ratio | 22.6% |
How did P0F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 06:58 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Egetis Therapeutics AB (publ) is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Langstrom | ABG Sundal Collier Sponsored |
| Erik Hultgård | Carnegie Investment Bank AB |
| Ulrik Trattner | Carnegie Investment Bank AB |